Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton Dickinson Raises 2021 Revenue, Adjusted EPS Guidance

08/05/2021 | 04:38am EDT

By Dave Sebastian

Becton Dickinson & Co. said it raised its fiscal 2021 revenue growth and adjusted earnings guidance ranges as it posted higher third-quarter profit and revenue.

The Franklin Lakes, N.J.-based medical-technology company on Thursday said it expects revenue to grow about 16.5% to 17% for the year, up from its prior guidance of 12% to 14%. It expects adjusted earnings of $12.85 to $12.95 a share, up from its prior outlook of $12.75 to $12.85 a share.

At the same time, the company said it has started to see some effect on elective procedures from the spread of the Delta variant of the Covid-19 virus in some U.S. states, and assumes some continuation of the trend.

Write to Dave Sebastian at dave.sebastian@wsj.com

(END) Dow Jones Newswires

08-05-21 0638ET

All news about BECTON, DICKINSON AND COMPANY
09/23BECTON DICKINSON AND : BD Joins the Race to Zero - Largest Alliance Dedicated to Achieving..
AQ
09/22BECTON DICKINSON AND : New BD Cell Analyzer Includes Spectral Analysis Capabilities
PU
09/22BD JOINS THE RACE TO ZERO : Largest Alliance Dedicated to Achieving Net Zero Emissions by ..
PR
09/21BECTON DICKINSON AND : District Of New Jersey Dismisses Putative Class Action Against Medi..
AQ
09/21BECTON DICKINSON AND : to Provide COVID-19 Rapid Test Kits for Washington State Schools
MT
09/21BECTON DICKINSON AND : BD Partners with Washington State in Back-to-School Testing Effort
PR
09/21Becton, Dickinson and Company Partners with Washington State in Back-To-School Testing ..
CI
09/08INSIDER SELL : Becton Dickinson
MT
09/08INSIDER SELL : Becton Dickinson &
MT
09/08BECTON, DICKINSON AND COMPANY : Ex-dividend day for
FA
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2021 20 009 M - -
Net income 2021 2 231 M - -
Net Debt 2021 14 336 M - -
P/E ratio 2021 32,9x
Yield 2021 1,46%
Capitalization 72 711 M 72 711 M -
EV / Sales 2021 4,35x
EV / Sales 2022 4,37x
Nbr of Employees 72 000
Free-Float 78,2%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 253,18 $
Average target price 269,87 $
Spread / Average Target 6,59%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Chris DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY1.18%72 711
ABBOTT LABORATORIES13.59%220 485
MEDTRONIC PLC11.00%174 982
HOYA CORPORATION29.36%62 143
ALIGN TECHNOLOGY, INC.35.72%57 302
SARTORIUS STEDIM BIOTECH77.82%55 891